You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 24, 2025

Patent: 10,130,645


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,130,645
Title:Use of thiopyrimidinecarboxamide for treating cancer
Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 ##STR00001## alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
Inventor(s): Zebala; John A. (Issaquah, WA), Maeda; Dean Y. (Seattle, WA), Schuler; Aaron D. (Auburn, WA)
Assignee: Syntrix Biosystems, Inc. (Auburn, WA)
Application Number:15/627,766
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Complexities of Patent Claims: A Comprehensive Analysis of the Patent Landscape

Introduction

Patent law in the United States is a complex and evolving field, crucial for innovators and businesses seeking to protect their intellectual property. This article delves into the intricacies of patent claims, using the context of U.S. Patent 10,130,645 as a case study, and provides a broader analysis of the patent landscape.

The Importance of Patent Claims

Patent claims are the heart of any patent application, as they define the scope of the invention and the rights granted to the patent holder. The business and legal value of a patent resides primarily in its claims, which must be carefully crafted to ensure they are both valid and enforceable[2].

Subject Matter Eligibility Under Section 101

One of the critical aspects of patent law is the subject matter eligibility under Section 101 of the U.S. Patent Act. This section determines what types of inventions are eligible for patent protection. The Supreme Court has established several key precedents:

  • Abstract Ideas: In cases like Parker v. Flook and Bilski v. Kappos, the Supreme Court has held that abstract ideas, even when implemented using a computer, are not patentable if they do not add significant innovation beyond the abstract idea itself[1].
  • Natural Laws: In Mayo Collaborative Services v. Prometheus Laboratories, Inc., the Court ruled that claims must contain additional elements beyond natural laws that are not well-understood, routine, and conventional to be patent-eligible[1].

Nonobviousness Under Section 103

Another fundamental requirement for patentability is nonobviousness under Section 103. This involves determining whether the invention would have been obvious to a person of ordinary skill in the pertinent art. The Supreme Court in Graham v. John Deere established the Graham factors, which include:

  • The scope and content of the prior art
  • The differences between the prior art and the claims at issue
  • The level of ordinary skill in the pertinent art
  • Whether the improvement is more than the predictable use of prior-art elements according to their established functions[3].

The Role of Inventorship

Determining the correct inventors is crucial for the validity of a patent. Inventorship focuses on the conception of the idea, defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. Only those who conceive the subject matter of at least one claim of the patent are considered inventors[5].

The Increasing Complexity of Patent Applications

The number of patent applications and the number of claims per application have been increasing significantly. From approximately 100,000 applications per year in the 1960s and 1970s to over 326,000 in 2001, the trend continues with technology facilitating both the filing and the complexity of patent applications. Some applications now include thousands of claims, making the review process increasingly challenging[2].

Automated Systems for Patent Claims Analysis

To address the growing complexity, automated systems like the Patent Matrix software have been developed. These systems automate the import of patent claims, parse the claims into their hierarchy, and provide compression and expansion functionality to facilitate rapid review and analysis[2].

Case Law and Its Impact

Several landmark cases have shaped the patent landscape:

  • Diamond v. Diehr: This case established that an invention using computer software can be patentable if it is part of a larger process that is not merely an abstract idea or mathematical algorithm[1].
  • Association for Molecular Pathology v. Myriad Genetics, Inc.: Here, the Supreme Court ruled that naturally occurring DNA sequences are not patentable, but synthetic DNA sequences (cDNA) can be patented[1].

Drafting Patent Claims

Drafting patent claims is a delicate process that requires careful consideration of various factors, including the scope of the invention, prior art, and the potential for future litigation. Resources like Chisum on Patents provide detailed guidance on drafting claims and interpreting patent law, ensuring that claims are both valid and enforceable[4].

The Impact of the America Invents Act

The America Invents Act of 2011 introduced significant changes to the U.S. patent system, shifting from a first-to-invent to a first-to-file system. This change has implications for the timing and strategy of filing patent applications and emphasizes the importance of prompt and accurate filing[4].

Key Takeaways

  • Subject Matter Eligibility: Ensure that the invention is eligible under Section 101 by avoiding abstract ideas and natural laws without additional innovative elements.
  • Nonobviousness: The invention must be nonobvious under Section 103, considering the Graham factors.
  • Inventorship: Correctly identify the inventors based on the conception of the idea.
  • Complexity of Claims: Use automated systems to manage the increasing complexity of patent claims.
  • Case Law: Stay updated with landmark cases that shape patent law and practice.

FAQs

What is the significance of Section 101 in patent law?

Section 101 determines the subject matter eligibility of an invention, ensuring that only certain types of inventions are eligible for patent protection. It excludes abstract ideas, natural laws, and other non-statutory subject matter.

How does the nonobviousness requirement under Section 103 impact patent applications?

The nonobviousness requirement ensures that the invention is not obvious to a person of ordinary skill in the pertinent art. This involves analyzing the prior art, differences between the prior art and the claims, and the level of ordinary skill.

Why is correct inventorship crucial for a patent?

Correct inventorship is essential because it affects the validity and enforceability of the patent. Errors in inventorship, especially those made with deceptive intent, can render the patent unenforceable.

How has the America Invents Act changed the patent landscape?

The America Invents Act shifted the U.S. patent system from first-to-invent to first-to-file, emphasizing the importance of prompt and accurate filing of patent applications.

What tools are available to manage the complexity of patent claims?

Automated systems like the Patent Matrix software help in importing, parsing, and analyzing patent claims, making it easier to review and manage the growing complexity of patent applications.

Sources

  1. BitLaw: Section 101 Subject Matter Eligibility Index.
  2. Google Patents: US20110138338A1 - Patent Claims Analysis System and Method.
  3. USPTO: AN ANALYSIS OF OBVIOUSNESS STANDARD IN PATENT LAW.
  4. LexisNexis: Chisum on Patents.
  5. Oregon State University: Determining Inventorship for US Patent Applications.

More… ↓

⤷  Try for Free

Details for Patent 10,130,645

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Genentech, Inc. ACTIVASE alteplase For Injection 103172 November 13, 1987 ⤷  Try for Free 2033-08-02
Genentech, Inc. CATHFLO ACTIVASE alteplase For Injection 103172 September 04, 2001 ⤷  Try for Free 2033-08-02
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 ⤷  Try for Free 2033-08-02
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.